NEW YORK — Proteomics testing firm Proteomics International Laboratories said on Tuesday that it, the Australian government, and the University of Western Australia will invest A$6 million (US$3.9 million) in funding to develop a biomarker analysis platform.

纽约——蛋白质组学检测公司Proteomics International Laboratories于周二表示，其与澳大利亚政府及西澳大利亚大学将共同投资600万澳元（约合390万美元），用于开发一个生物标志物分析平台。

According to Proteomics International, Australia's Commonwealth Government National Collaborative Research Infrastructure Strategy will provide A$4 million to the effort over the next three years, with the Perth-based company and UWA contributing an additional A$1 million each.

根据蛋白质组学国际公司（Proteomics International）的消息，澳大利亚联邦政府国家合作研究基础设施战略（NCRIS）将在未来三年内为该项目提供400万澳元，而位于珀斯的该公司和西澳大学（UWA）将各自额外贡献100万澳元。

With the A$6 million, Proteomics International and UWA aim to build a nationally accredited technology platform for protein biomarker analysis at their jointly run WA Proteomics Facility. The platform will support the use of diagnostic tests for clinical use, as well as testing of large-scale sample sets for agricultural and environmental applications..

通过这600万澳元，蛋白质组学国际公司和西澳大学旨在他们共同运营的西澳蛋白质组学设施中建立一个国家认可的蛋白质生物标志物分析技术平台。该平台将支持临床诊断测试的使用，以及用于农业和环境应用的大规模样本集的测试。

'This facility can become a national hub for precision diagnostic testing across clinical and agricultural proteomics,' Richard Lipscombe, managing director of Proteomics International, said in a statement.

“这一设施可以成为临床和农业蛋白质组学领域精准诊断测试的国家级中心，”蛋白质组学国际公司董事总经理理查德·利普科姆在一份声明中表示。

Earlier this year, Proteomics International

今年早些时候，蛋白质组学国际

opened

打开

a California-based CLIA lab through which it is offering its PromarkerD proteomic blood test for identifying individuals at risk of diabetes-related chronic kidney disease in the US.

一家位于加利福尼亚的CLIA实验室，通过该实验室，它正在美国提供其PromarkerD蛋白质组血液测试，以识别有糖尿病相关慢性肾病风险的个体。